# Achieve Life Sciences, Inc. (QUIT)

Source page: https://stoqly.net/companies/quit

- **Ticker:** QUIT (Nasdaq)
- **Sector:** Health Care / In Vitro & In Vivo Diagnostic Substances
- **SEC CIK:** 0000949858
- **Latest annual report:** 10-K filed 2026-03-24 (https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm)
- **Data updated:** 2026-11-11

## What the company does

Achieve Life Sciences develops cytisinicline, a drug candidate intended to help people stop smoking cigarettes or using nicotine e-cigarettes. Cytisinicline is a naturally occurring substance that acts on nicotine receptors in the brain and is intended to reduce cravings and withdrawal symptoms. The company has developed a 3 mg tablet and treatment schedules of 6 or 12 weeks. The product is investigational and has not been approved by the FDA in the United States.

Achieve focuses on developing cytisinicline for smoking cessation and vaping cessation, with the goal of seeking approval in the United States and other markets. It holds an exclusive license and supply agreement with Sopharma to develop and commercialize the drug outside Sopharma’s territories, which are mainly in Central and Eastern Europe and also include Scandinavia, North Africa, the Middle East, Central Asia and Vietnam. Sopharma has marketed a cytisinicline product in its territories for over 20 years. Achieve’s application for smoking cessation is under FDA review, and its vaping treatment remains in clinical development.

Achieve relies on outside manufacturers to make cytisinicline. It has a supply agreement with Sopharma and is transferring production to U.S.-based manufacturer Adare Pharma Solutions, which is intended to provide additional U.S. manufacturing capacity.

## Key figures

- **Last close:** $6.78 on 2026-11-09
- **Market cap:** $715M
- **EPS, trailing 12 months:** −$1.33
- **Free cash flow:** −$49.5M
- **Return on equity:** −257.7%
- **Change in share count:** +35.9%
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.2M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/quit/figures.csv

| US$ millions | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | — | — | 0 | 0 | — | — | — | — | — | — |
| Net income | -1 | -11 | -13 | -16 | -15 | -33 | -42 | -30 | -40 | -55 |
| Diluted EPS (US$) | -581.25 | -22.07 | -72.29 | -39.76 | -5.42 | -4.08 | -4.00 | -1.50 | -1.24 | -1.25 |
| Operating cash flow | 0 | -9 | -11 | -15 | -13 | -29 | -38 | -24 | -30 | -49 |
| Free cash flow | 0 | — | -11 | -15 | -13 | — | — | -25 | — | -49 |
| Cash | 10 | 5 | 15 | 17 | 36 | 43 | 25 | 16 | 34 | 36 |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.